Posted by Michael Wonder on 30 Jan 2023
Nanoscope Therapeutics receives fast track designation by the FDA for MCO-010 for the treatment of Stargardt disease
30 January 2023 - Nanoscope Therapeutics today announced that the US FDA has granted fast track designation to MCO-010, an ambient light activatable multi-characteristic opsin optogenetic monotherapy to restore vision in blind patients, for the treatment of Stargardt disease to improve visual function.
In September 2022, enrollment was completed in the Phase 2 open-label STARLIGHT clinical trial of MCO-010 in six patients with advanced vision loss due to a clinical or genetic diagnosis of Stargardt disease.
